Table 3.
Aged 45–64 years | Aged 65–84 years | Aged 85 + years | ||||
---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | HR | 95% CI | |
Men | ||||||
Levothyroxine treatment | 1.84 | 0.68–5.00 | 1.01 | 0.84–1.22 | 0.97 | 0.71–1.34 |
No treatment | Ref | Ref | Ref | |||
Women | ||||||
Levothyroxine treatment | 0.71 | 0.26–1.95 | 1.06 | 0.95–1.18 | 0.99 | 0.86–1.14. |
No treatment | Ref | Ref | Ref | |||
Alla | ||||||
Levothyroxine treatment | 1.05 | 0.51–2.15 | 1.05 | 0.95–1.15 | 0.99 | 0.87–1.13 |
No treatment | Ref | Ref | Ref |
Full Model adjusted for age, educational level, immigrant status, marital status, neighborhood deprivation, comorbidities, and cardiovascular medications
aGender was added in the fully adjusted model